Scholarlink

Background <p>HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis in patients with HER2-positive non-metastatic BC.</p> Methods <p>267 HER2-positive BC were enrolled between January 2010 and December 2011. Stabilized inverse probability treatment weighting (sIPTW) was used to balance baseline characteristics. Real-world disease-free survival (DFS) and overall survival (OS) was analyzed.</p> Results <p>The median follow-up time was 10.3&#xa0;years (interquartile range: 9.4–10.8&#xa0;years). HER2/CEP17 ratio of &gt; 7.0 was defined as the HER2 ultra-positive group; a HER2/CEP17 ratio of ≤ 7.0 was defined as the HER2 normal-positive group. After sIPTW adjustment, no differences were observed in DFS and OS when anti-HER2 therapy was unknown, and similarly in the patients who were recorded as not receive trastuzumab (all <i>p</i> &gt; 0.05). Interestingly, HER2 ultra-positive group had a worse DFS than the normal-positive group (hazard ratio [HR] = 2.72, <i>p</i> = 0.02), but there was no difference in OS (<i>p</i> = 0.30) in patients did receive trastuzumab. The multivariate Cox models also showed that the HER2 ultra-positive had worse DFS than HER2 normal-positive patients (HR = 3.71; <i>p</i> &lt; 0.01). </p> Conclusion <p>For non-metastatic HER2-positive BC with or without trastuzumab treatment, the HER2/CEP17 ratio did not predict DFS and OS. However, our study supported that HER2 ultra-positive group had a worse DFS than the normal-positive group among non-metastatic HER2-positive BC patients receiving trastuzumab; therefore, this could be a potential predictor of DFS in these patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月18日

查看全文
  • Fangchao Zheng,
  • Feng Du,
  • Zixuan Yang,
  • Xue Wang,
  • Jian Yue,
  • Yun Ling,
  • Peng Yuan

摘要

Background

HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis in patients with HER2-positive non-metastatic BC.

Methods

267 HER2-positive BC were enrolled between January 2010 and December 2011. Stabilized inverse probability treatment weighting (sIPTW) was used to balance baseline characteristics. Real-world disease-free survival (DFS) and overall survival (OS) was analyzed.

Results

The median follow-up time was 10.3 years (interquartile range: 9.4–10.8 years). HER2/CEP17 ratio of > 7.0 was defined as the HER2 ultra-positive group; a HER2/CEP17 ratio of ≤ 7.0 was defined as the HER2 normal-positive group. After sIPTW adjustment, no differences were observed in DFS and OS when anti-HER2 therapy was unknown, and similarly in the patients who were recorded as not receive trastuzumab (all p > 0.05). Interestingly, HER2 ultra-positive group had a worse DFS than the normal-positive group (hazard ratio [HR] = 2.72, p = 0.02), but there was no difference in OS (p = 0.30) in patients did receive trastuzumab. The multivariate Cox models also showed that the HER2 ultra-positive had worse DFS than HER2 normal-positive patients (HR = 3.71; p < 0.01).

Conclusion

For non-metastatic HER2-positive BC with or without trastuzumab treatment, the HER2/CEP17 ratio did not predict DFS and OS. However, our study supported that HER2 ultra-positive group had a worse DFS than the normal-positive group among non-metastatic HER2-positive BC patients receiving trastuzumab; therefore, this could be a potential predictor of DFS in these patients.